Artwork

Contenu fourni par Anne Philippi. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Anne Philippi ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Player FM - Application Podcast
Mettez-vous hors ligne avec l'application Player FM !

Lars Christian Wilde - On markets, psilocybin & Compass Pathways.

59:39
 
Partager
 

Manage episode 286473802 series 2591035
Contenu fourni par Anne Philippi. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Anne Philippi ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Today, my guest is Lars Christian Wilde, the President, Chief Business Officer and Co‑founder of Compass Pathways. Compass is a “mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.” as they describe themselves. Compass was one of the first companies engaging in a bigger vision of the substance psilocybin. But back to Lars. He is a special guest to me, since I like his open mind. I remember talking to Lars in one of our first podcasts about vaccine against depression in the future. I also remember how openly Lars talked about his treatment-resistant depression and anxiety disorder and the effects it had on him and the people in his life. He told me about his treatment with psilocybin, that helped him tremendously to begin a new life with a different mental health set. I am always a fan of people, especially entrepreneurs in the psychedelic field, that share their psychedelic experiences and are personally affected by the power of psychedelic substances. In 2020 lot of things have happened at Compass Pathways. In September 2020 the company became a public company, listing their stock on Nasdaq and raising $146.6 million. Compass became one of the most exciting company in the field. Lars and I catch up, what is happening in the Compass World right now. How does a psychedelic public company feels and works different? How does the Compass and Sheppard Pratt collaboration look like, since Compass is opening a Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, to do more research. Their psychiatry department exists since the 1800s. We talk about how Compass works with the Charité hospital in Berlin and how to do conduct a study in times of Covid at all, we discuss COMP360, a psilocybin therapy trial for treatment-resistant depression designed by Compass for future treatments of depression (https://compasspathways.com/)

Hosted on Acast. See acast.com/privacy for more information.

  continue reading

89 episodes

Artwork
iconPartager
 
Manage episode 286473802 series 2591035
Contenu fourni par Anne Philippi. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Anne Philippi ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Today, my guest is Lars Christian Wilde, the President, Chief Business Officer and Co‑founder of Compass Pathways. Compass is a “mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.” as they describe themselves. Compass was one of the first companies engaging in a bigger vision of the substance psilocybin. But back to Lars. He is a special guest to me, since I like his open mind. I remember talking to Lars in one of our first podcasts about vaccine against depression in the future. I also remember how openly Lars talked about his treatment-resistant depression and anxiety disorder and the effects it had on him and the people in his life. He told me about his treatment with psilocybin, that helped him tremendously to begin a new life with a different mental health set. I am always a fan of people, especially entrepreneurs in the psychedelic field, that share their psychedelic experiences and are personally affected by the power of psychedelic substances. In 2020 lot of things have happened at Compass Pathways. In September 2020 the company became a public company, listing their stock on Nasdaq and raising $146.6 million. Compass became one of the most exciting company in the field. Lars and I catch up, what is happening in the Compass World right now. How does a psychedelic public company feels and works different? How does the Compass and Sheppard Pratt collaboration look like, since Compass is opening a Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, to do more research. Their psychiatry department exists since the 1800s. We talk about how Compass works with the Charité hospital in Berlin and how to do conduct a study in times of Covid at all, we discuss COMP360, a psilocybin therapy trial for treatment-resistant depression designed by Compass for future treatments of depression (https://compasspathways.com/)

Hosted on Acast. See acast.com/privacy for more information.

  continue reading

89 episodes

Wszystkie odcinki

×
 
Loading …

Bienvenue sur Lecteur FM!

Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.

 

Guide de référence rapide